## 1 SARS-CoV-2 variants in the making: Sequential intrahost evolution and forward 2 transmissions in the context of persistent infections

- 3 Ana S. Gonzalez-Reiche<sup>1</sup>, Hala Alshammary<sup>2,4</sup>, Sarah Schaefer<sup>3</sup>, Gopi Patel<sup>3</sup>, Jose Polanco<sup>2,4</sup>, Juan
- 4 Manuel Carreño<sup>2,4</sup>, Angela A. Amoako<sup>2,4</sup>, Aria Rooker<sup>2,4</sup>, Christian Cognigni<sup>2,4</sup>, Daniel Floda<sup>1</sup>,
- 5 Adriana van de Guchte<sup>1</sup>, Zain Khalil<sup>1</sup>, Keith Farrugia<sup>1</sup>, Nima Assad<sup>5</sup>, Jian Zhang<sup>1</sup>, Bremy
- 6 Alburquerque<sup>1,5</sup>, PARIS/PSP study group<sup>2,4</sup>, Levy Sominsky<sup>2,4</sup>, Charles Gleason<sup>2,4</sup> Komal
- 7 Srivastava<sup>2,4</sup>, Robert Sebra<sup>1,8,9,10</sup>, Juan David Ramirez<sup>6,11</sup>, Radhika Banu<sup>6</sup>, Paras Shrestha<sup>6</sup>, Florian
- 8 Krammer<sup>2,4,6</sup>, Alberto Paniz-Mondolfi<sup>6</sup>, Emilia Mia Sordillo<sup>6†</sup>, Viviana Simon<sup>2,3,4,6,7,†</sup>, Harm van
- 9 Bakel<sup> $1,8,\dagger$ </sup>
- Department of Genetics and Genomic Sciences, Icahn School of Medicine at Mount Sinai,
   New York, NY 10029, USA
- Department of Microbiology, Icahn School of Medicine at Mount Sinai, New York, NY 10029,
   USA
- Division of Infectious Diseases, Department of Medicine, Icahn School of Medicine at Mount
   Sinai, New York, NY 10029, USA
- Center for Vaccine Research and Pandemic Preparedness (C-VARPP), Icahn School of Medicine at Mount Sinai, New York, NY, USA
- Graduate School of Biomedical Sciences, Icahn School of Medicine at Mount Sinai, New York, NY 10029, USA
- Department of Pathology, Molecular, and Cell-Based Medicine, Icahn School of Medicine at Mount Sinai, New York, NY 10029, USA
- The Global Health and Emerging Pathogens Institute, Icahn School of Medicine at Mount
   Sinai, New York, NY 10029, USA
- Icahn Genomics Institute, Icahn School of Medicine at Mount Sinai, New York, NY 10029,
   USA
- Black Family Stem Cell Institute, Icahn School of Medicine at Mount Sinai, New York, NY,
   10029, USA
- 28 10. Sema4, a Mount Sinai venture, Stamford CT, 06902
- 11. Centro de Investigaciones en Microbiología y Biotecnología-UR (CIMBIUR), Facultad de
   Ciencias Naturales, Universidad del Rosario, Bogotá, Colombia.
- 31
- 32 <u>Corresponding authors/senior authors:</u>
- 33 † Dr. Emilia Mia Sordillo (Emilia.Sordillo@mountsinai.org), Dr. Viviana Simon
   34 (viviana.simon@mssm.edu), and Dr. Harm van Bakel (harm.vanbakel@mssm.edu)
- 35
- 36 <u>PARIS/PSP study group</u>:
- 37 Giulio Kleiner, Dalles Andre, Katherine F Beach, Maria C Bermúdez-González, Gianna Cai, Neko
- 38 Lyttle, Lubbertus C F Mulder, Annika Oostenink, Ashley Beathrese T Salimbangon, Gagandeep
- 39 Singh, Morgan van Kesteren, Brian Monahan, Jake Mauldin, Mahmoud Awawda

## 40 ABSTRACT – 193 WORDS

41 Persistent severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infections have 42 been reported in immune-compromised individuals and people undergoing immune-modulatory 43 treatments. Although intrahost evolution has been documented, to our knowledge, no direct 44 evidence of subsequent transmission and stepwise adaptation is available.

Here we describe sequential persistent SARS-CoV-2 infections in three individuals that led 45 46 to the emergence, forward transmission, and continued evolution of a new Omicron sublineage, 47 BA.1.23, over an eight-month period. The initially transmitted BA.1.23 variant encoded seven 48 additional amino acid substitutions within the spike protein (E96D, R346T, L455W, K458M, 49 A484V, H681R, A688V), and displayed substantial resistance to neutralization by sera from 50 boosted and/or Omicron BA.1-infected study participants. Subsequent continued BA.1.23 51 replication resulted in additional substitutions in the spike protein (S254F, N448S, F456L, M458K, 52 F981L, S982L) as well as in five other virus proteins.

53 Our findings demonstrate that the Omicron BA.1 lineage can diverge further from its 54 already exceptionally mutated genome during persistent infection in more than one host, and also 55 document ongoing transmission of these novel variants. There is an urgent need to implement 56 strategies to prevent prolonged SARS-CoV-2 replication and to limit the spread of newly 57 emerging, neutralization-resistant variants in vulnerable patients.

## 59 INTRODUCTION

60 The genomic landscape of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-61 2) has been shaped by the emergence of antigenically diverse variants of concern  $(VOC)^1$ . These 62 viral variants carry mutations that render them more transmissible, more fusogenic, and/or permit escape not only from infection but also vaccine-induced immunity<sup>2-4</sup>. Some variants such as the 63 64 Omicron VOCs, which swept the globe starting November 2021, also display partial or complete resistance to therapeutic or prophylactic monoclonal treatments<sup>5</sup>. Over the past ten months 65 66 Omicron sublineages with increasing numbers of mutations in spike have continued to emerge 67 (e.g., BA.1, BA.2, BA.4/5), posing great challenges to the containment of SARS-CoV-2 spread 68 and providing the rationale for formulation of bivalent SARS-CoV-2 booster vaccines that include 69 an Omicron BA.1 or BA.5 spike in addition to the ancestral spike.

70 Most patients with coronavirus disease 2019 (COVID-19) clear the virus upon resolution 71 of the acute infection. However, ongoing SARS-CoV-2 replication has been documented in a 72 subset of immunocompromised individuals. In these chronically infected cases, recovery of 73 infectious virus over several months and stepwise acquisition of mutations in spike has been 74 observed, pointing to positive selection<sup>6-13</sup>. It has been speculated that prolonged intrahost viral 75 evolution played a role in the emergence of several SARS-CoV-2 VOCs such as Alpha and Omicron<sup>14,15</sup>, but clear evidence for forward transmissions of mutated variants from chronic 76 77 infection cases has been lacking.

78 We describe herein a primary case of persistent SARS-CoV-2 Omicron BA.1 infection 79 marked by intrahost evolution of a variant (Omicron BA.1.23) encoding seven additional amino 80 acid substitutions in the already antigenically distinct Omicron BA.1 spike protein, and that 81 resulted in at least five further cases of Omicron BA.1.23 infection. Persistent infections 82 documented in two of these cases (one lasting four weeks, the other more than four months) were 83 associated with continued BA.1.23 evolution and acquisition of additional mutations within and 84 outside of spike. Although the variants that evolved in the persistently infected cases during the 85 cumulative eight-month period reveal unique constellations of mutations in each, they also strongly point to convergent viral evolution with other co-circulating SARS-CoV-2 lineages. 86 87 Notably, most amino acid changes occurred at positions known to confer either immune escape<sup>16,17</sup> or altered viral fusogenicity<sup>18-20</sup>. Some of these escape mutations in BA.1.23 are now signature 88

- 89 substitutions in emerging Omicron lineages such as BA.2.75.2, indicating that persistent viral
- 90 replication in the context of suboptimal immune responses is an important driver of SARS-CoV-
- 91 2 diversification.

#### 92 **Results**

#### 93 Emergence of a novel BA.1 sublineage through intrahost evolution.

94 We performed genomic analysis of serially collected nasopharyngeal (NP) and anterior nares (AN) 95 samples from an immunocompromised patient (P1) with diffuse B-cell lymphoma and persistent 96 SARS-CoV-2 Omicron BA.1 replication between December 2021 and March 2022. Over a 12-97 week period, we documented the accumulation of nine amino acid substitutions in the spike protein 98 N-terminal domain (NTD), the receptor binding domain (RBD), and in the S1/S2 furin cleavage 99 site (FCS) (Fig. 1) within the same patient. The first four mutations R346T, K458M, E484V, and 100 A688V were detected simultaneously 40 days after the initial SARS-CoV-2 diagnosis and were 101 fixed. Two weeks later (day 64), L167T and the FCS mutation P681Y were detected in addition 102 to the four initial mutations. During the following weeks (day 72 and day 81), two different viral 103 populations emerged each carrying shared (L455W) as well as additional distinct signature 104 mutations (E96D on day 72, S477D on day 81). All but one of the mutations observed in the 105 consensus sequences outside the spike gene were non-synonymous, providing further support for 106 positive intrahost selection of spike protein changes with competitive replication advantages.

107

108 Forward spread confirms transmission potential of the novel BA.1.23 sublineage. 109 Background health system-wide SARS-CoV-2 genomic surveillance conducted by the Mount 110 Sinai Pathogen Surveillance Program (MS-PSP) during the same time period identified three other 111 patients harboring SARS-CoV-2 Omicron variants that shared seven of the amino acid 112 substitutions found in the index case P1 (E96D, R346T, L455W, K458M, A484V, H681R, 113 A688V), and were consistent with multiple forward transmissions based on the timeline of 114 infection (Fig. 2, Table 1). Although viral isolation failed for specimens available from the index 115 case, we successfully cultured SARS-CoV-2 from the initial positive specimens of the subsequent 116 cases, confirming the transmission of replication-competent virus. All three forward transmissions 117 were detected in patients with underlying hematologic malignancies.

Lastly, two additional related SARS-CoV-2 genomes from the NYC area were identified from the GISAID (Global Initiative on Sharing Avian Influenza Data) database (**Fig. 2**). Based on the metadata provided, these two cases differed by age and gender from our cases, consistent with independent but limited community spread of this new Omicron BA.1 sub-variant. All

transmission cases contained one synonymous change in Orf1a (T6001C) previously only observed at day 72 in the index case (**Extended Data Fig. 1**), narrowing the time window of the first transmission to a few weeks following day 64. As of August 2022, the most recent case was detected in mid-April 2022 and the last SARS-CoV-2 positive specimen from a forward transmission case (P3) was collected in September 2022. Taken together, the presence of a unique combination of mutations in all six cases is indicative of forward transmission of this novel Omicron subvariant, which received the BA.1.23 Pango lineage designation.

129

#### 130 Sequential persistent infections drive further intrahost evolution of BA.1.23

131 While patient P2 cleared the BA.1.23 infection, patients P3 and P4 both developed persistent 132 infections (Fig. 2 and 3A). The MS-PSP continued monitoring these patients during follow-up 133 visits and hospitalizations. Patient P4 remained positive by nucleic acid amplification tests 134 (NAAT) for four weeks, with acquisition of an additional mutation in the spike RBD (S:V445A) 135 within one week of the initial positive test (Fig. 2 and 3A). Patient P3 developed a much longer 136 persistent infection lasting for more than four months. Genomic analysis of all 10 serially collected 137 specimens from P3 identified 14 additional amino acid substitutions throughout the viral genome 138 (Fig. 2B and Extended Data Fig. 1). The most recent specimen collected 131 days after P3's 139 COVID-19 onset contained 11 additional amino acid substitutions compared to the originally 140 transmitted BA.1.23 variant. These included six substitutions in the spike NTD (S254F), RBD 141 (N448S, F456L, reversion of 458M to K), and S2 (reversion of 981L to F, S982L); as well as five 142 substitutions in other SARS-CoV-2 proteins (ORF1a nsp3: T1001/183I, K1795/977Q, 143 ORF1ab nsp11 S4398/6L; ORF1ab nsp12: G5063/671S; and ORF7a: T39I/T24I). Notably, two 144 spike amino acid reversions to the WA1/USA (S:M458K) or BA.1 (S:F981L) state were 145 accompanied by changes at neighboring positions (S:F456L and S:S982L) (Fig. 2B and Extended 146 Data Fig. 1).

We further identified multiple positions with intra-host single nucleotide variants that were present in only a minority of the SARS-CoV-2 viral populations, hereafter referred to as minor single nucleotide variants (mSNVs), within each of the three persistent infection cases (P1, P3, and P4). In some cases, we detected mSNVs within or outside the spike gene in earlier specimens, prior to their fixation in subsequent specimens from the same patient (Figure 2B and Extended Data

152 Figure 1.2). We also observed numerous positions with mSNVs that persisted across multiple 153 sequential specimens without becoming dominant. This was most notable for patient P3: between 154 the first specimen collected on day 101 and the ninth specimen collected on day 218, the number 155 of positions with mSNVs at a level >10% in two or more specimens increased gradually from 0 to 156 19 - eventually outnumbering the consensus sequence changes by a factor of three (Fig. 2B and 157 **Extended Data Fig. 3**). Approximately half of these mutations occurred within the spike gene, 158 where nonsynonymous mSNVs were clustered in the S1 (NTD:S254F, RBD:K356T, S371F, 159 P384L, F456L, K458M, and FCS:N679K) and S2 (D936Y,V963F, N978D, L981F, S982L, 160 E1195G) domains (Fig. B2 and Extended Data Fig. 4). Mutations at these positions are rare at 161 the consensus level, with a maximum prevalence of 0.1% in the GISAID reference database [as of 162 2022-09-10]. The final specimen collected two weeks later, on day 232, showed eleven additional 163 substitutions (including five at positions with prior mSNVs) and two positions with mSNVs (Fig. 164 2B, Extended Data Fig. 3 and Supplementary Table S1). The progressive accumulation of 165 mutations as well as the low prevalence of the specific substitutions in co-circulating SARS-CoV-166 2 lineages in NYC at the time, makes it unlikely that the mutated genotypes are the result of 167 recombination with other viral variants. The large shift in mutational profile may reflect a fitness 168 advantage of the dominant variant in this specimen. Thus, intra-host adaptation occurs with 169 different dynamics pointing to bottlenecks and competing selection pressures resulting in the 170 appearance and disappearance of specific mutations.

171

#### 172 Impact of treatment and host immunity on BA.1.23 evolution

173 To determine the potential impact of SARS-CoV-2 antiviral treatments on intrahost evolution we 174 examined the medication histories of patients P1 (index), P2, P3 and P4 (Fig. 3). We also assessed 175 SARS-CoV-2 spike binding antibody levels using available serological data from clinical tests. 176 The index patient P1 was vaccinated at the time of admission with two doses of an unspecified 177 vaccine administered six months and one week before hospitalization. A third vaccine dose was 178 administered two days after admission. Additional SARS-CoV-2 antiviral treatments included a 179 course of remdesivir on days 1-6 and a dose of Gamunex IgG on day 9 (Fig. 3D). Moderate titers 180 of SARS-CoV-2 antibodies were detected on day 38, around the time the first intra-host mutations 181 were found (Fig. 2C). These titers could be due to residual antibodies from the Gamunex IgG

treatment, an immune response to vaccination and/or infection, or a combination of treatment and host response. Notably, the detection of the first three spike mutations followed an increase in NAAT cycle thresholds (Ct) on day 30, suggesting a potential selection bottleneck around this time (**Fig. 2A**).

Patient P2 was fully vaccinated and had high titers of SARS-CoV-2 antibodies when assayed three months before and one month after their single positive SARS-CoV-2 NAAT (**Fig. 3B**). This patient also received a one-month course of nirmatrelvir/ritonavir (Paxlovid<sup>TM</sup>) (**Fig. 3D**). The combination of high levels of host antibodies and antiviral treatment likely explains why this patient did not develop a persistent infection.

191 The long-term case P3 was fully vaccinated at the time of their first positive test and received a 3week course of nirmatrelvir/ritonavir (Paxlovid<sup>TM</sup>). However, no SARS-CoV-2 antibodies were 192 193 detected in serological assays performed during the first 4 months of their persistent infection (Fig. 194 **3B**). Notably, during this time we also did not detect new substitutions in the BA.1.23 lineage, 195 despite indications of active viral replication based on consistently low NAAT Ct values (less than 196 25) in NP and AN samples. Active replication was confirmed by isolation of replication-competent 197 SARS-CoV-2 from five specimens collected between study days 101-147. Notably, the 198 appearance of new intra-host substitutions during the last month of persistent infection occurred 199 around the time of detection of SARS-CoV-2 antibodies at levels close to the lower limit of the 200 serological assay (Fig. 3). P3 did not receive antibody therapy during their hospitalization, 201 indicating that the seroconversion was the result of a delayed and weak host immune response.

202 Patient P4 was unvaccinated and received bebtelovimab mAb after their first positive SARS-CoV-203 2 PCR test, followed by a course of nirmatrelvir/ritonavir. P4 had low SARS-CoV-2 antibody titers 204 at the time of the first positive PCR prior to the mAb treatment (Fig. 3B). The S:V445A mutation 205 that emerged in this patient may be associated with the mAb treatment, as it was shown to result 206 in a 111-fold reduction in susceptibility to bebtelovimab for viral variants carrying this mutation in pseudotyped virus-like particle (VLP) neutralization assays<sup>21</sup>. We did not find SARS-CoV-2 207 mutations associated with remdesivir<sup>22-27</sup> or nirmatrelvir/ritonavir resistance<sup>28</sup> in any of the 208 209 patients treated with these drugs.

210

## 211 Serum neutralization profile of Omicron BA.1.23

212 Neutralization of Omicron BA.1 isolates by sera from convalescent or twice boosted individuals 213 is strongly reduced compared to the levels obtained for neutralization of the ancestral strains<sup>29-31</sup>. 214 We therefore assessed the degree of neutralizing activity of BA.1.23 (BA.1 + S:E96D, R346T, 215 L455W, K548M, E484V, P681R, A688V) compared to Omicron BA1 (B.1.1.529), and the 216 ancestral SARS-CoV-2 (USA-WA1/2020, WA). We used a multi-cycle replication assay in which 217 serum is present continuously to best mimic physiological in vivo conditions. We selected sera 218 from two subsets of PARIS study participants representing distinct levels of immunity. The first 219 panel of sera tested was collected before and after booster vaccination while the second set of 220 samples was obtained before and after Omicron BA.1 breakthrough infection.

221 Prior to booster vaccination with monovalent SARS-CoV-2 RNA-based vaccines, neutralization 222 of BA.1, BA.1.23 and the WA1/USA were comparable (geometric mean titer; GMT WA1: 31; 223 GMT BA.1: 12; GMT BA.1.23: 9; Fig. 4A). However, 4/9 and 6/9 samples failed to display any 224 neutralization activity against BA.1 and BA.1.23 respectively while this was true for only 2/9 225 samples when looking at activity against the ancestral virus. After booster vaccination, the loss in 226 neutralization for BA.1.23 was greater than 15-fold compared to only a three-fold reduction for 227 BA.1 relative to WA1/USA (geometric mean titer; GMT WA1: 674; BA.1:234; GMT BA.1.23: 228 45; Fig. 4A). Of note, the loss of neutralization activity for BA.1 measured here is less than what 229 has previously been reported which could be due to assay variation in combination with the limited 230 number of samples tested<sup>29</sup>.

231 We next looked how sera collected before and after breakthrough infection would neutralize 232 BA.1.23. We noted a significant difference in neutralization activity for BA.1.23 but not BA.1 233 compared to WA1 in the samples collected before and after BA.1 breakthrough infection (Fig. 234 **4B**). Prior to BA.1 infection, the difference was >25-fold with 3/11 samples having undetectable 235 neutralization activity for BA.1.23 and 5-fold difference for BA.1 (GMT WA1: 406; GMT BA.1: 236 83; GMT BA.1.23: 16; Fig. 4B). After infection, neutralization titers increased for all three viruses 237 reducing the difference to two-fold for BA.1 and 8-fold for BA.1.23 (GMT WA1: 2134; GMT 238 BA.1: 1026; GMT BA.1.23: 253; Fig. 4B).

Lastly, we analyzed sera collected from patient P2 at different time points (e.g., before booster

- 240 vaccination, after booster vaccination but before BA.1.23 infection, and at two time points after
- 241 infection with BA.1.23). P2 mounted neutralizing antibodies after booster vaccination with the

- ancestral variant being neutralized >25 times more efficiently than BA.1 or BA.1.23 (Fig. 4C).
- 243 One month after breakthrough infection with BA.1.23, neutralization of all three viruses increased
- relative to the titers measured after booster vaccination but to very different degrees (e.g. WA1: 6-
- fold, BA.1:45 fold, BA.1.23: 25-fold). Of note, two months after infection, the BA.1 titers
- remained stable, while neutralization of the ancestral virus as well as BA.1.23 declined equally.
- 247 Collectively these results indicate that BA.1.23 is significantly more resistant to neutralization than
- the parental BA.1 variant.

## 250 **DISCUSSION**

251 It has been speculated that the emergence of antigenically diverse SARS-CoV-2 variants such as 252 Omicron result from intrahost viral evolution driven initially by suboptimal immune responses and 253 then spread by forward transmissions. Our data demonstrate that intrahost evolution of SARS-254 CoV-2 during persistent infection in immunocompromised individuals can drive the emergence 255 and spread of novel (sub)variants with extensive mutations in key antigenic regions, even in the 256 context of the already highly mutated Omicron lineage. Further sequential evolution in 257 transmission cases shows that rapid divergence can occur stepwise and persist in small numbers 258 of individuals, complicating early detection of novel variants.

259 The most extensive changes in the evolution of the BA.1.23 lineage were seen during its 260 emergence in patient P1 and its subsequent divergence in patient P3 over a total period of 8 months. 261 Based on available clinical testing data, both patients were initially negative for SARS-CoV-2 262 antibodies but seroconverted to moderate to low levels around the time spike mutations were 263 accumulating. These conditions are likely optimal for the selection of immune escape mutations 264 and provide an explanation for the clustering of BA.1.23-specific changes in the spike protein. It 265 is important to note that the antiviral treatments administered over limited time periods as 266 monotherapies (e.g., monoclonal antibodies, remdesivir, and nirmatrelvir/ritonavir (Paxlovid<sup>TM</sup>) 267 failed to eliminate the persistent infection, highlighting the need for improved or potential 268 combination therapy tailored for these special situations.

269 During the initial emergence of the BA.1.23 lineage in index patient P1 mutations were 270 concentrated in the spike protein. The amino acid substitutions or positions at which changes 271 accumulated have been associated with neutralization escape (e.g., R346T, E484V, S477)<sup>16,17</sup>, increased angiotensin converting enzyme 2 (ACE2) binding avidity (e.g., R346T, L455W)<sup>32</sup>, 272 improved viral fusogenicity (e.g., P681R/Y)<sup>18</sup>, or a predicted increase in fitness (e.g., positions 273 346, 484 and 681)<sup>33</sup>. Subsequent stepwise changes in patient P3 occurred more broadly throughout 274 275 the SARS-CoV-2 genome. The RBD mutations N448S and F456L present in the most recent 276 specimen from P3 are within the ACE2 binding region with potential for changes in binding 277 affinity and antibody escape<sup>32</sup>. Mutations outside the spike mapped to nonstructural proteins, many 278 of which have previously been detected in other VOCs such as Nsp3 T183I (Alpha),

Nsp3\_K977Q (Gamma), Nsp12\_G671S (Delta AY.\* and Omicron BA.2.75). Although the effects
of these mutations have not been characterized, they occurred in the virus polymerase subunit
(Nsp12) and in proteins with antagonistic activity towards the host's innate immunity (Nsp3,
ORF6, ORF7a, ORF9b)<sup>34</sup>.

283 Consistent with the extensive changes in the spike protein, resistance of the transmitted BA.1.23 284 variant to neutralization was substantially increased compared to the ancestral SARS-CoV-2 strain 285 as well as to BA.1 Omicron. This was true both for sera collected before and after monovalent 286 booster vaccination as well as after BA.1 breakthrough infection (Figure 4). Escape from 287 neutralization was likely mediated by the combination of R346T, L455W, K458M, and E/A484V 288 within the receptor binding region of spike. Of note, substitutions at position R346 are found in 289 several Omicron sublineages (e.g., BA.4, BA.5) and subvariants (e.g., BA.2.72.2, BA.4.6/BF.7 290 (R346T), BA.4.7 (R346S), and BA.5.9 (R346I))<sup>35</sup>. These variants were not circulating at the time 291 of BA.1.23 emergence pointing to convergent evolution in the context of suboptimal immune 292 responses.

293 We further found that changes in minority viral populations can greatly increase the spectrum of 294 mutations during persistent infection beyond what is observed at the consensus level. Viral 'quasi-295 species' have been described for pandemic coronaviruses such as SARS-CoV-1, Middle Eastern Respiratory Syndrome Coronavirus (MERS-CoV) and SARS-CoV-2<sup>36-42</sup>, but their role remains to 296 297 be fully elucidated<sup>43</sup>. Interestingly, mSNVs predominantly occurred in conserved regions and 298 remained present in multiple sequential specimens. Only a small subset of these mutations became 299 dominant in later specimens. We speculate that these viral populations enable sub-optimal 300 mutations to persist within the host, increasing the likelihood for the emergence of compensatory 301 mutations that offset their fitness defects.

Despite careful monitoring, we did not encounter new BA.1.23 cases in our routine SARS-CoV-2 surveillance or in the GISAID database between June-September 2022, suggesting that the lineage has not spread further beyond the initial outbreak. This may be due to increased caution by immunocompromised patients to avoid contacts that could increase their risk of infection. We also note that patients P1, P3 and P4 were hospitalized for long stretches of time during their persistent infections, further limiting community exposure. Finally, the limited transmission could reflect a reduced fitness of BA.1.23 compared to contemporary lineages. Notable in this respect is that the

309 emergence of the BA.1.23 lineage coincided with the general displacement of BA.1 by BA.2

310 sublineages in the NYC area, in particular BA.2.12.1, which dominated SARS-CoV-2 cases during

311 the spring and early summer of 2022. A longer observation period with continued background

312 surveillance will be needed to rapidly identify any potential re-emergence of BA.1.23 in patients

313 other than the ones included in this study.

314 Our findings add to the accumulating knowledge regarding SARS-CoV-2 persistent infections,

315 and document subsequent forward transmissions. Furthermore, we show that persistent infections

316 can drive emergence of viral variants with the potential to spread to other individuals, some of

317 whom may themselves develop prolonged infections, and thereby establish a pathway for

318 continued virus evolution. This warrants genomic monitoring of persistent infections in particular,

319 and further underscores the need to limit the duration of viral infection. Improved early detection

320 of novel SARS-CoV-2 variants and forward transmission tracking, a better understanding of the

321 selection processes driving SARS-CoV-2 evolution and the role of mSNVs, as well as therapies

322 that limit virus persistence and shedding, are essential to reduce the emergence of highly mutated

323 viral variants in the future.

#### 325 MATERIALS AND METHODS

## 326 <u>Molecular SARS-CoV-2 diagnostics</u>

327 SARS-CoV-2 molecular diagnostic testing was performed in the Molecular Microbiology 328 Laboratories of the MSHS Clinical Laboratory by nucleic acid amplification tests (NAAT) that 329 have been validated for nasopharyngeal (NP), anterior nares (AN) swabs, and saliva specimens. 330 All but one positive sample included in this study were tested using the PerkinElmer® New 331 Coronavirus Nucleic Acid Detection Kit which provides qualitative detection of nucleic acid from 332 SARS-CoV-2. It includes two SARS-CoV-2 targets (ORF1ab, N) and one internal positive control 333 (IC; bacteriophage MS2). Cycle threshold (Ct) values are generated for all three targets and 334 provide a quantitative estimate of the viral load. The only other positive sample that was run on 335 another testing platform was the first specimen of the index case (P1). It was tested as a point of 336 care test (POC) using the cobas<sup>®</sup> Liat<sup>®</sup> System (cobas<sup>®</sup> SARS-CoV-2 & Influenza A/B) assay, and 337 the biospecimen was discarded prior to transfer to the MS-PSP.

338

#### 339 <u>The Mount Sinai Pathogen Surveillance Program (MS-PSP)</u>

340 The Mount Sinai Pathogen Surveillance Program (MS-PSP) has profiled the evolving landscape 341 of SARS-CoV-2 in New York City (NYC) since the beginning of the pandemic<sup>44,45</sup>. We routinely 342 perform complete viral genome sequencing of randomly selected contemporaneous SARS-CoV-2 343 positive specimens collected from patients seeking care at our health system. Residual respiratory 344 specimens (NP, AN swabs) were collected after completion of the diagnostic process, as part of 345 the Mount Sinai Pathogen Surveillance Program. The program was reviewed and approved by the 346 Mount Sinai Hospital (MSH) Institutional Review Board (IRB-13-00981). The detailed 347 investigation into persistent SARS-CoV-2 infections in patients receiving care at the Mount Sinai 348 Health System was separately reviewed and approved by the MSH IRB (IRB-22-00760).

349

## 350 <u>Human Serum Samples</u>

We used a panel of sera collected as part of the longitudinal observational PARIS (Protection Associated with Rapid Immunity to SARS-CoV-2) cohort<sup>46</sup>. This study follows health care workers longitudinally since April 2020. Samples were selected based on the study participants

354 different levels of immunity (before and after booster vaccination, as well as before and after 355 Omicron BA.1 infection). The study was reviewed and approved by the MSH IRB (IRB-20-356 03374). All participants signed written consent forms prior to sample and data collection and 357 provided permission for sample banking and sharing. Sera collected before and after SARS-CoV-358 2 booster vaccination (N=9 participants, 18 sera) as well as before and after Omicron BA.1 break-359 through infections (N=11 participants, 22 sera) were selected for testing in this study (see 360 Supplementary Table S3 for infection, vaccine and demographics information). 361 In addition, patient P2 participated in another of our observational study (IRB-16-01215). They

361 In addition, participated in another of our observational study (IRB-10-01213). They
 362 provided written consent prior to biospecimen and data collection. Several serum samples from
 363 this patient before and after BA.1.23 infection were available for neutralization assays.

The 44 sera (40 PARIS, 4 from P2) from our observational cohorts are unique to this study and are not publicly available.

366

## 367 <u>RNA extraction and SARS-CoV-2 genome sequencing</u>

368 RNA was extracted using the Chemagic <sup>™</sup> Viral DNA/RNA 300 Kit H96 (PerkinElmer, CMG-369 1033-S) on the automated Chemagic <sup>™</sup> 360 instrument (PerkinElmer, 2024-0020) from 300uL of 370 viral transport media per the manufacturer's protocol. cDNA synthesis followed by whole genome 371 amplification with two custom primer panel sets targeting 1.5 and 2kb regions across the SARS-CoV-2 genome was performed as previously described<sup>44</sup> with the addition of new oligonucleotides 372 to minimize amplicon dropout for Omicron lineages derived from PANGO lineage B.1.1.529 373 374 (Supplementary Table S4). Paired-end (2x150bp) Nextera XT (Illumina, cat. FC-131-1096) 375 libraries prepared from amplicons were sequenced on a MiSeq instrument. SARS-CoV-2 genomes were assembled using a custom reference-based pipeline as previously described<sup>44</sup>. The final 376 377 average sequencing depth per genome ranged between ~135k to ~415k reads.

378

## 379 Analysis of minor nucleotide variants

Minority intra-host single nucleotide variants (mSNVs) were annotated when present in both reads of paired-end reads of a single sample and at a minimum frequency of 0.1 (10%). A second quality control filter was applied by only including positions for which mSNVs were present in more than

383 one sample from the study (from different time pointes) or for positions that changed at the 384 consensus level at any point of the investigation.

385

#### 386 *Phylogenetic analysis*

387 Global background SARS-CoV-2 sequences were downloaded from the GISAID EpiCOV 388 database (as of 2022-08-30). The GISAID database was queried for the novel mutations observed 389 in P1-P4 sequences to identify their closest matches. Sequence hits were confirmed by their Mash distance<sup>47</sup>. For this, a genome sketch was generated with Mash v.2.3 from the sanitized alignment 390 391 of the global sequences filtered for lineages BA.1.\* as produced by Nextstrain<sup>1,48</sup> v11 for SARS-392 CoV-2 with default parameters (https://github.com/nextstrain/ncov). This allowed pairwise 393 comparisons of our data with high-quality global sequences with available metadata. Maximum 394 likelihood phylogenetic inferences of the MS-PSP SARS-CoV-2 genomes, including the closest 395 sequence matches and all other BA.\* lineage sequences from the MS-PSP surveillance program, 396 were done using an Omicron BA.\* and New York State-focused background with proximity 397 subsampling scheme with Nextstrain under the GTR+G model of nucleotide substitution. Branch 398 support was assessed with the ultrafast bootstrap method with 1000 replicates in IQ-TREE 399 multicore version 2.1.2 [PMID: 29077904, 25371430]. Clade and lineage assignments were done with Nextclade CLI v3.2 (2021-11-04)<sup>49</sup> and with PANGO-v1.8 (pangolin v3.1.17, pangoLEARN 400 v.2022-04-22) <sup>50,51</sup>. 401

402

# 403 <u>SARS-CoV-2 viral cultures</u>

404 Replication-competent SARS-CoV-2 was obtained as previously described<sup>29</sup>. Briefly, Vero-E6 405 cells expressing transmembrane serine protease 2 (TMPRSS2) (BPS Biosciences, catalog (cat.) 406 no. 78081) were cultured in Dulbecco's modified Eagle medium containing 10% heat-inactivated 407 fetal bovine serum and 1% minimum essential medium (MEM) Amino Acids Solution, 408 supplemented with 100 U/ml penicillin, 100 µg/ml streptomycin, 100 µg/ml normocin, and 3 µg/ml 409 puromycin. 200ul of viral transport media from the nasopharyngeal or anterior nares swab 410 specimen was added to Vero-E6-TMPRSS2 cells in culture media supplemented with 2% heat-411 inactivated fetal bovine serum, 100g/ml normocin, and 0.5 µg/ml amphotericin B. Cultures were

maintained for a maximum of 10 days. Culture supernatants were collected and clarified by
centrifugation (3,739g for 5 min) upon the appearance of cytopathic effects. Viral cultures were

- 414 successful for the initial specimens obtained from P2, P3, and P4, but failed for all P1 specimens.
- 415

## 416 <u>*Titration and concentration of viral isolates*</u>

417 Viral stocks were sequence-verified and then titered using the 50% tissue culture infectious dose 418 (TCID<sub>50</sub>) method on Vero-E6-TMPRSS2 cells. Based on sequencing verification, viral isolate 419 from P3 (PV56567) was selected for further experiments. Since the initial viral titer of the 420 expanded BA.1. 23 PV56567 viral stock was too low (4x10<sup>2</sup> TCID<sub>50</sub>/ml) to perform 421 microneutralization assays, we concentrated the viral isolate 4x using Pierce<sup>TM</sup> Protein 422 Concentrator PES, 100K MWCO (Thermo Scientific, Catalog number: 88537) columns as 423 described by the manufacturer. Briefly, culture supernatant was collected upon appearance of a 424 cytopathic effect (CPE), clarified by centrifugation (3,739g, 5min) and then concentrated. Titers 425 after concentration were  $1.27 \times 10^{5}$  TCID<sub>50</sub>/ml.

426

## 427 <u>Micro-neutralization assays with replication-competent SARS-CoV-2 isolates</u>

Sera collected from three different groups of study participants were used to assess the neutralization of wild type (WA1), BA.1, and BA.1.23 SARS-CoV-2 isolates. The first panel of samples includes sera collected before and after mRNA SARS-CoV-2 booster vaccination (N: 9, PARIS cohort), the second panel includes sera collected before and after BA.1 Omicron breakthrough infection (N:11, PARIS cohort). The last series includes longitudinal samples from P2, the first of the forward transmission case, collected prior as well as after the infection with BA.1.23.

Sera from study participants were serially diluted (three-fold) from a starting dilution of 1:10 using infection media consisting of minimum essential media (MEM, Gibco) supplemented with 2 mM L-glutamine, 0.1% sodium bicarbonate (w/v, Gibco), 10 mM 4-(2-hydroxyethyl)-1piperazineethanesulfonic acid (HEPES, Gibco), 100 U/ml penicillin, 100  $\mu$ g/ml streptomycin (Gibco) and 0.2% bovine serum albumin (MP Biomedicals). Diluted sera were incubated for one hour with 10,000 TCID<sub>50</sub> of the three different viruses at room temperature. After the incubation,

441 120 µl of the serum-virus mix were transferred to Vero-E6-TMPRSS2 (plated in 96 well plates the prior day) and incubated at 37°C, 5% CO<sub>2</sub> for one hour. The serum-virus mix was removed and 442 443 100 µl/well of the diluted sera were added in addition to 100 µl/well of MEM 2% FBS. The plates 444 were incubated for 48 hours at 37°C incubation. The cells were fixed (200 µl/well, 10% 445 formaldehyde solution) overnight at 4°C prior to staining an anti-SARS nucleoprotein antibody produced in house (mAb 1C7C7)<sup>52</sup>. All procedures above were performed in the Biosafety Level 446 447 3 (BSL-3) facility at the Icahn School of Medicine at Mount Sinai following approved standard safety guidelines. The nucleoprotein staining was performed as previously described<sup>29</sup>. The 448 449 analyses were performed using Prism 9 software (GraphPad).

450

## 451 <u>Statistics</u>

452 Statistical analyses were performed using Prism 9 software (GraphPad). A one-way ANOVA with

453 Tukey's multiple comparisons test was used to compare the neutralization titers for the three

454 viruses.

#### 455 ACKNOWLEDGMENTS

We thank the Mount Sinai Hospital and School Leadership, in particular Dr. David Reich, Dr. Dennis Charney, and Dr. Carlos Cordon-Cardo, for their ongoing support of the MS-PSP throughout the pandemic. We thank the laboratory technologists and staff in the Molecular Microbiology Laboratories and the Rapid Response Laboratories of the Mount Sinai Health System since without their assistance and help, none of this surveillance work would be possible.

We gratefully acknowledge the authors and originating and submitting laboratories of sequences from GISAID's EpiCoV (<u>www.gisaid.org</u>) that were used as background for our phylogenetic inferences.

464

## 465 **FUNDING SOURCES**

466 The work reported was, in part, supported by a contract from the National Institute of Allergy and 467 Infectious Diseases (75N93021C00014, Option 12A) awarded to the Center for Research on 468 Influenza Pathogenesis and Transmission and by an Option to the Collaborative Influenza Vaccine 469 Innovation Centers (CIVIC) contract 75N93019C00051 as part of the SARS-CoV-2 Assessment of 470 Viral Evolution (SAVE) Program, a contract from the National Institute of Allergy and Infectious 471 Diseases (HHSN272201400008C, Option 20) awarded to the Center for Research on Influenza 472 Pathogenesis, and awards (S10OD026880 and S10OD030463) from the NIH Office of Research 473 Infrastructure Programs. The Mount Sinai Pathogen Surveillance Program is supported in part by 474 Institutional funds from the Icahn School of Medicine as well as the Mount Sinai Hospital.

475

## 476 AUTHOR CONTRIBUTION STATEMENT

- 477 Conceptualization: A.S.G.-R., H.A., E.M.S., V.S., H.v.B. Sample acquisition: S.S, G.P, J.P., A.A.,
- 478 A.R., C.C., D.F., L.S., C.G., K.S., J.D.R., R.B., P.S, A.P-M, PSP-PARIS Study Group. Sequencing
- 479 and genome assembly: A.vd.G, K.F., Z.K., J.Z., B.A., R.S. Methodology: A.S.G.-R., H.A., N.A.,
- 480 J.M.C, F.K. Investigation: A.S.G.-R., H.A., J.M.C., E.M.S., V.S., H.v.B. Visualization: A.S.G.-
- 481 R., H.A., V.S., H.v.B. Funding Acquisition: E.M.S., V.S., H.v.B. Project administration: K.S.,
- 482 E.M.S., V.S., H.v.B. Supervision: E.M.S., V.S., H.v.B. Writing First draft: A.S.G.-R., H.A.,
- 483 H.v.B. Writing Review and editing: A.S.G.-R., H.A., J.M.C, F.K. E.M.S., V.S., H.v.B.

484

## 485 **COMPETING INTERESTS**

486 The Icahn School of Medicine at Mount Sinai has filed patent applications relating to SARS-CoV-487 2 serological assays (U.S. Provisional Application Numbers: 62/994,252, 63/018,457, 63/020,503 488 and 63/024.436) and NDV-based SARS-CoV-2 vaccines (U.S. Provisional Application Number: 489 63/251,020) which list Florian Krammer as co-inventor. Viviana Simon is also listed on the 490 serological assay patent application as co-inventor. Patent applications were submitted by the 491 Icahn School of Medicine at Mount Sinai. Mount Sinai has spun out a company, Kantaro, to market 492 serological tests for SARS-CoV-2. Florian Krammer has consulted for Merck and Pfizer (before 493 2020), and is currently consulting for Pfizer, Third Rock Ventures, Segirus and Avimex. The 494 Krammer laboratory is also collaborating with Pfizer on animal models of SARS-CoV-2. Robert 495 Sebra is VP of Technology Development and a stockholder at Sema4, a Mount Sinai Venture. This 496 work, however, was conducted solely at Icahn School of Medicine at Mount Sinai. 497

# 498 ADDITIONAL INFORMATION STATEMENT

- 499 Correspondence and requests for materials should be addressed to Drs. Sordillo, Simon and/or van500 Bakel.
- 501

## 502 DATA AND CODE AVAILABILITY STATEMENT

503 Custom code used in this study is available at https://github.com/mjsull/COVID\_pipe. Complete 504 genome sequences for the viral isolates cultured from nasal swabs (BA.1 and BA.1.23) are 505 available in GISAID.

#### 506 **References**

- 507 1 Nextstrain build for novel coronavirus SARS-CoV-2 (2020).
- 508
   2
   DeGrace, M. M. *et al.* Defining the risk of SARS-CoV-2 variants on immune protection. *Nature* 

   509
   **605**, 640-652, doi:10.1038/s41586-022-04690-5 (2022).
- 510 3 Flemming, A. Omicron, the great escape artist. *Nat Rev Immunol* 22, 75, doi:10.1038/s41577-022511 00676-6 (2022).
- 512 4 Plante, J. A. *et al.* The variant gambit: COVID-19's next move. *Cell Host Microbe* 29, 508-515,
  513 doi:10.1016/j.chom.2021.02.020 (2021).
- 514 5 VanBlargan, L. A. *et al.* An infectious SARS-CoV-2 B.1.1.529 Omicron virus escapes 515 neutralization by therapeutic monoclonal antibodies. *Nat Med* **28**, 490-495, doi:10.1038/s41591-516 021-01678-y (2022).
- 517 6 Corey, L. *et al.* SARS-CoV-2 Variants in Patients with Immunosuppression. *N Engl J Med* 385,
  518 562-566, doi:10.1056/NEJMsb2104756 (2021).
- Avanzato, V. A. *et al.* Case Study: Prolonged Infectious SARS-CoV-2 Shedding from an
  Asymptomatic Immunocompromised Individual with Cancer. *Cell* 183, 1901-1912 e1909,
  doi:10.1016/j.cell.2020.10.049 (2020).
- 522 8 Choi, B. *et al.* Persistence and Evolution of SARS-CoV-2 in an Immunocompromised Host. *N Engl*523 *J Med* 383, 2291-2293, doi:10.1056/NEJMc2031364 (2020).
- 524 9 Kemp, S. A. *et al.* SARS-CoV-2 evolution during treatment of chronic infection. *Nature* 592, 277 525 282, doi:10.1038/s41586-021-03291-y (2021).
- Truong, T. T. *et al.* Increased viral variants in children and young adults with impaired humoral
  immunity and persistent SARS-CoV-2 infection: A consecutive case series. *EBioMedicine* 67,
  103355, doi:10.1016/j.ebiom.2021.103355 (2021).
- 529 11 Scherer, E. M. *et al.* SARS-CoV-2 Evolution and Immune Escape in Immunocompromised
  530 Patients. *N Engl J Med* 386, 2436-2438, doi:10.1056/NEJMc2202861 (2022).
- 531 12 Cele, S. *et al.* SARS-CoV-2 prolonged infection during advanced HIV disease evolves extensive
  532 immune escape. *Cell Host Microbe* 30, 154-162 e155, doi:10.1016/j.chom.2022.01.005 (2022).
- Hoffman, S. A. *et al.* SARS-CoV-2 Neutralization Resistance Mutations in Patient with HIV/AIDS,
  California, USA. *Emerg Infect Dis* 27, 2720-2723, doi:10.3201/eid2710.211461 (2021).
- Martin, D. P. *et al.* Selection analysis identifies unusual clustered mutational changes in Omicron
  lineage BA.1 that likely impact Spike function. *bioRxiv*, 2022.2001.2014.476382,
  doi:10.1101/2022.01.14.476382 (2022).
- 53815(CoG-UK), C.-G. C. U. Preliminary genomic characterisation of an emergent SARS-CoV-2 lineage539in the UK defined by a novel set of spike mutations, <<u>https://virological.org/t/preliminary-genomic-</u>

540 characterisation-of-an-emergent-sars-cov-2-lineage-in-the-uk-defined-by-a-novel-set-of-spike-

- 541 <u>mutations/563</u>> (2020).
- Greaney, A. J. *et al.* Mapping mutations to the SARS-CoV-2 RBD that escape binding by different
  classes of antibodies. *Nat Commun* 12, 4196, doi:10.1038/s41467-021-24435-8 (2021).
- 544 17 Starr, T. N. et al. Deep Mutational Scanning of SARS-CoV-2 Receptor Binding Domain Reveals 545 Constraints on Folding and ACE2 Binding. Cell 182, 1295-1310 e1220, 546 doi:10.1016/j.cell.2020.08.012 (2020).
- 54718Escalera, A. *et al.* Mutations in SARS-CoV-2 variants of concern link to increased spike cleavage548and virus transmission. *Cell Host Microbe*, doi:10.1016/j.chom.2022.01.006 (2022).
- 549 19 Saito, A. *et al.* Enhanced fusogenicity and pathogenicity of SARS-CoV-2 Delta P681R mutation.
   550 *Nature* 602, 300-306, doi:10.1038/s41586-021-04266-9 (2022).
- 551 20 Meng, B. *et al.* Altered TMPRSS2 usage by SARS-CoV-2 Omicron impacts infectivity and 552 fusogenicity. *Nature* **603**, 706-714, doi:10.1038/s41586-022-04474-x (2022).
- 55321Fact sheet for healtcare providers: Emergency use authorization for bebtelovimab., <</th>554https://pi.lilly.com/eua/bebtelovimab-eua-factsheet-hcp.pdf#page=12> (2022).
- 555 22 Szemiel, A. M. *et al.* In vitro selection of Remdesivir resistance suggests evolutionary predictability
  of SARS-CoV-2. *PLoS Pathog* 17, e1009929, doi:10.1371/journal.ppat.1009929 (2021).
- Gandhi, S. *et al.* De novo emergence of a remdesivir resistance mutation during treatment of
  persistent SARS-CoV-2 infection in an immunocompromised patient: a case report. *Nat Commun*13, 1547, doi:10.1038/s41467-022-29104-y (2022).
- Checkmahomed, L. *et al.* In Vitro Selection of Remdesivir-Resistant SARS-CoV-2 Demonstrates
  High Barrier to Resistance. *Antimicrob Agents Chemother* 66, e0019822, doi:10.1128/aac.0019822 (2022).
- 56325Agostini, M. L. *et al.* Coronavirus Susceptibility to the Antiviral Remdesivir (GS-5734) Is564Mediated by the Viral Polymerase and the Proofreading Exoribonuclease. *mBio* 9,565doi:10.1128/mBio.00221-18 (2018).
- Martinot, M. *et al.* Emerging RNA-Dependent RNA Polymerase Mutation in a Remdesivir-Treated
  B-cell Immunodeficient Patient With Protracted Coronavirus Disease 2019. *Clin Infect Dis* 73, e1762-e1765, doi:10.1093/cid/ciaa1474 (2021).
- Tchesnokov, E. P. *et al.* Template-dependent inhibition of coronavirus RNA-dependent RNA
  polymerase by remdesivir reveals a second mechanism of action. *J Biol Chem* 295, 16156-16165,
  doi:10.1074/jbc.AC120.015720 (2020).
- 572 28 Zhou, Y. *et al.* Nirmatrelvir Resistant SARS-CoV-2 Variants with High Fitness in Vitro. *bioRxiv*,
  573 2022.2006.2006.494921, doi:10.1101/2022.06.06.494921 (2022).

- 574 29 Carreno, J. M. *et al.* Activity of convalescent and vaccine serum against SARS-CoV-2 Omicron.
- 575 *Nature* **602**, 682-688, doi:10.1038/s41586-022-04399-5 (2022).
- 576 30 Cele, S. *et al.* Omicron extensively but incompletely escapes Pfizer BNT162b2 neutralization.
  577 *Nature* 602, 654-656, doi:10.1038/s41586-021-04387-1 (2022).
- 578 31 Dejnirattisai, W. *et al.* SARS-CoV-2 Omicron-B.1.1.529 leads to widespread escape from 579 neutralizing antibody responses. *Cell* **185**, 467-484 e415, doi:10.1016/j.cell.2021.12.046 (2022).
- 58032OmicronReceptorBindingDomainDeepMutationalScanningData,581<<u>https://jbloomlab.github.io/SARS-CoV-2-RBD\_DMS\_Omicron/</u>> (
- 582 33 Obermeyer, F. *et al.* Analysis of 6.4 million SARS-CoV-2 genomes identifies mutations associated
  583 with fitness. *Science* 376, 1327-1332, doi:10.1126/science.abm1208 (2022).
- 584 34 Thorne, L. G. *et al.* Evolution of enhanced innate immune evasion by SARS-CoV-2. *Nature* 602,
  585 487-495, doi:10.1038/s41586-021-04352-y (2022).
- 586
   35
   Jian, F. *et al.* Further humoral immunity evasion of emerging SARS-CoV-2 BA.4 and BA.5

   587
   subvariants. *bioRxiv*, 2022.2008.2009.503384, doi:10.1101/2022.08.09.503384 (2022).
- Jary, A. *et al.* Evolution of viral quasispecies during SARS-CoV-2 infection. *Clin Microbiol Infect* 26, 1560 e1561-1560 e1564, doi:10.1016/j.cmi.2020.07.032 (2020).
- Xu, D., Zhang, Z. & Wang, F. S. SARS-associated coronavirus quasispecies in individual patients.
   *N Engl J Med* 350, 1366-1367, doi:10.1056/NEJMc032421 (2004).
- 59238Karamitros, T. *et al.* SARS-CoV-2 exhibits intra-host genomic plasticity and low-frequency593polymorphic quasispecies. J Clin Virol 131, 104585, doi:10.1016/j.jcv.2020.104585 (2020).
- 59439Briese, T. *et al.* Middle East respiratory syndrome coronavirus quasispecies that include595homologues of human isolates revealed through whole-genome analysis and virus cultured from596dromedary camels in Saudi Arabia. *mBio* 5, e01146-01114, doi:10.1128/mBio.01146-14 (2014).
- 597 40 Tonkin-Hill, G. *et al.* Patterns of within-host genetic diversity in SARS-CoV-2. *Elife* **10**, 598 doi:10.7554/eLife.66857 (2021).
- 59941Valesano, A. L. *et al.* Temporal dynamics of SARS-CoV-2 mutation accumulation within and600across infected hosts. *PLoS Pathog* 17, e1009499, doi:10.1371/journal.ppat.1009499 (2021).
- 601 42 Wang, Y. *et al.* Intra-host variation and evolutionary dynamics of SARS-CoV-2 populations in
- 602 COVID-19 patients. *Genome Med* **13**, 30, doi:10.1186/s13073-021-00847-5 (2021).
- Sun, F. *et al.* SARS-CoV-2 Quasispecies Provides an Advantage Mutation Pool for the Epidemic
  Variants. *Microbiol Spectr* 9, e0026121, doi:10.1128/Spectrum.00261-21 (2021).
- 60544Gonzalez-Reiche, A. S. *et al.* Introductions and early spread of SARS-CoV-2 in the New York City606area. Science, doi:10.1126/science.abc1917 (2020).

- Hernandez, M. M. *et al.* Molecular evidence of SARS-CoV-2 in New York before the first
  pandemic wave. *Nat Commun* 12, 3463, doi:10.1038/s41467-021-23688-7 (2021).
- 609 46 Simon, V. *et al.* PARIS and SPARTA: Finding the Achilles' Heel of SARS-CoV-2. *mSphere* 7,
  610 e0017922, doi:10.1128/msphere.00179-22 (2022).
- 611 47 Ondov, B. D. *et al.* Mash: fast genome and metagenome distance estimation using MinHash.
  612 *Genome Biol* 17, 132, doi:10.1186/s13059-016-0997-x (2016).
- 48 Hadfield, J. *et al.* Nextstrain: real-time tracking of pathogen evolution. *Bioinformatics* 34, 4121614 4123, doi:10.1093/bioinformatics/bty407 (2018).
- Aksamentov, I. R., Cornelius; Hodcroft, Emma B.; Neher, Richard A. Nextclade: clade assignment,
  mutation calling and quality control for viral genomes. *Journal of Open Source Software* 6, 3773,
  doi:10.21105/joss.03773 (2021).
- 618 50 Phylogenetic assignment of named global outbreak lineages v. 2020-05-19 (2020).
- 619 51 O'Toole, A. *et al.* Tracking the international spread of SARS-CoV-2 lineages B.1.1.7 and
  620 B.1.351/501Y-V2 with grinch. *Wellcome Open Res* 6, 121,
  621 doi:10.12688/wellcomeopenres.16661.2 (2021).
- 622 52 Amanat, F. *et al.* An In Vitro Microneutralization Assay for SARS-CoV-2 Serology and Drug
  623 Screening. *Curr Protoc Microbiol* 58, e108, doi:10.1002/cpmc.108 (2020).

# **TABLES**

626	Table 1: Spike mutations detected in the sequenced cases.	
-----	---	--

Pat	Sex	Age	Days from P1 first positive	GISAID Accession number	Source	Lineage	Mutations in Spike relative to earliest sample (BA.1: A67V, T95I, Y145D, L212I, G339D, S371L, S373P, S375F, K417N, N440K, G446S, S477N, T478K, E484A, Q493R, G496S, Q498R, N501Y, Y505H, T547K, D614G, H655Y, N679K, P681H, N764K, D796Y, N856K, Q954H, N969K, L981F) #																			
			specime n	(EPI_ISL)			E96	L176	S254	R346	S371	V445	N448	L455	F456	K458	S477	E484	T547	S680	P681	A688	L981	S982		
			0	N/A	This study																					
			23	11897513	This study	BA.1					L							А			Н	V	F			
		61- 65			40	11897516	This study	BA.1				Т	L					М		V			Н	V	F	
P1	М		48	11178997	This study	BA.1.23				Т	L					М		V			Н	V	F			
			64	11179080	This study	BA.1.23		F		Т	L					М		V			Y	V	F			
			72	11685451	This study	BA.1.23	D			Т	L			W		М		V			Н	V	F			
			81	11897525	This study	BA.1.23+		F		Т	L			W		М	D	V			Y	V	F			
P2	F	66- 70	76	11685480	This study	BA.1.23	D			Т	L			W		М		V		А	Н	V	F			
			101	12422465	This study	BA.1.23	D			Т	L			W		М		V			R	V	F			
			111	13350580	This study	BA.1.23	D			Т	L			W		М		V			R	V	F			
			114	12711034	This study	BA.1.23	D			Т	L			W		М		V			R	V	F			
P3	М	36- 40	130	13350591	This study	BA.1.23+	D			Т	F			W		М		V			R	V	F			
			147	n.s.*	This study	BA.1.23	D			Т	L			W		М		V			R	V	F			
			192	n.s.*	This study	BA.1.23+	D			Т	F			W		М		V			R	V	F			
			209	n.s.*	This study	BA.1.23+	D			Т	F			W		М		V			R	V	F			

			213	n.s.*	This study	BA.1.23	D		Т	L			W		М	V		R	V	F	
			218	n.s.*	This study	BA.1.23+	D		Т	F			W		М	V		R	V	F	
			232	n.s.*	This study	BA.1.23+	D	F	Т	F		S	W	L		V		R	V		L
			104	n.s.*	This study	BA.1.23+	D		Т	F			W		М	V	K	R	V	F	
Р4	F	61-	111	12961673	This study	BA.1.23	D		Т	L			W		М	V		R	V	F	
	F	65	125	12896972	This study	BA.1.23+	D		Т	L	А		W		М	V		R	V	F	
			132	n.s.*	This study	BA.1.23+	D		Т	L			W	L	М	V		R	V	F	
S1	F	81- 85	78	11628400	Howard et al. 2022. GISAI D	BA.1.23	D		Т	L			W		М	V		R	V		
82	F	26- 30	79	11696379	Howard et al. 2022. GISAI D	BA.1.23	D		Т	L			W		М	V		R	V		

\* n.s.: Consensus not submitted due to presence of >10 intrahost single nucleotide variants. N/A: not sequenced . # Mutations in bold correspond to changes at positions already mutated in BA.1. 

# 629 FIGURES

# Figure 1



# 632 Figure 1. Intrahost emergence of an Omicron BA.1.23 subvariant

- 633 Multiple sequence alignment of the SARS-CoV-2 spike protein showing the appearance of
- 634 nucleotide and amino acid substitutions in the spike protein in sequential specimens obtained from
- 635 the index case (Patient 1, P1).



#### 638 Figure 2. Forward transmission of the Omicron BA.1.23 subvariant

639 A) Maximum likelihood phylogenetic subtree with SARS-CoV-2 (BA.1) sequences from the 640 persistent infection case P1 and the onward transmissions (P2, P3, P4), in a global background 641 of sequences available in GISAID. Branches are colored to identify the patient. The number of 642 days after the first SARS-CoV-2 positive specimen of P1 is indicated in brackets. Sibling 643 clusters of BA.1 and other sublineages are collapsed for easier visualization. The x-axis shows 644 the number of nucleotide substitutions relative to the root of the phylogenetic tree. Bootstrap 645 support values above 70% are shown for the un-collapsed branches. The distinct BA.1 646 subvariant that was transmitted was designated as PANGO lineage BA.1.23.

B) Frequency of single nucleotide variants (SNV), and amino acid substitutions for SARS-CoV-647 648 2 genomic positions with consensus changes from ancestral Wuhan-1 and Omicron BA.1. 649 Positions with mixed nucleotides below consensus are also shown for intrahost SNVs 650 (mSNVs) seen in more than one time point. The sequenced specimens are shown sequentially 651 for patient 1 (P1) with prolonged BA.1 infection and transmission cases of BA.1.23 (P2, P3 652 and P4). The viral genomes from P1 show progressive accumulation of mutations in the N-653 terminal domain (NTD), receptor binding domain (RBD), and S1/S2 furin cleavage site (FCS); 654 The same constellation of mutations was subsequently detected in three documented 655 transmission cases (P2, P3 and P4). The number of days since the first positive test in P1 is 656 shown on the left, with the number of days after the first positive test for each patient between 657 brackets. The mutation frequencies within the Spike protein are shown in red, and for non-658 Spike genome regions in blue. Positions are numbered according to the reference genome 659 sequence NC 045512.2. Arrows on the left indicate the likely window of transmission from 660 the index patient between days 64-72.

# Figure 3



Days since first positive SARS-CoV-2 test from index case

## 662 Figure 3. Timeline of BA.1.23 evolution compared to antibody levels and treatments

- 663 A) The timeline of BA.1.23 infected patients (top) is shown together with nucleic acid
- amplification test (NAAT) SARS-CoV-2 (N gene) cycle threshold (Ct) values for respiratory
- specimens, for different diagnostic methods (bottom). Empty markers indicate negative tests
  by alternative diagnostic tests with no Ct value readout (LumiraDxTM).
- B) Number of nucleotide substitutions in the consensus sequence relative to Omicron BA.1 in thesequenced specimens.
- 669 C) SARS-CoV-2 spike binding IgG antibody levels for P1- P4. Antibody levels are shown in
   arbitrary units per mL (AU/mL). Available vaccine information is indicated.
- 671 D) Timeline of SARS-CoV-2 antiviral treatments received by P1-P4. Treatment duration is
- 672 indicated by the length of the bar.



# Figure 4. The Omicron BA.1.23 subvariant displays strongly reduced neutralizing activity compared to the parental Omicron variant as well as ancestral SARS-CoV-2 variant.

- A) Absolute neutralization titers (left) and fold reduction (right) for WA-1, BA.1 and BA.1.23
   variants by paired sera from study participants collected before and after booster vaccination.
   The two samples with levels below detection for WA-1 were excluded from the fold-change
   calculation shown in the right panel.
- B) Absolute neutralization titers (left) and fold-reduction (right) for WA-1, BA.1 and BA.1.23
  isolates by sera from study participants who experienced breakthrough infection with BA.1.
  Data for paired sera from 11 participants collected before and after BA.1 infection are shown.
- 684 C) Absolute neutralization titers (left) and fold-changes in neutralization titers relative to the post
   booster timepoint (right) for each of the isolates (WA-1, BA.1 and BA.1.23) by sera collected
   from patient P2 before and after BA1.23 infection. The first vertical dotted line (left) represents
   the third vaccine dose. The second vertical dotted line (right) indicates the infection with the
   BA.1.23 variant.
- 689 GMT denotes mean geometric mean of the inhibitory dilution 50% (ID50) values. The 690 horizontal dotted line represents the limit of detection (10). Samples with neutralization titers 691 below the level of detection were assigned the neutralization value of 5 (equaling to half of the 692 limit of detection). Fold changes in neutralization are A one-way ANOVA with Tukey's 693 multiple comparison test was used to compare the neutralization titers before and after booster 694 vaccination or BA.1 breakthrough infection. Significant p values (<0.05) are indicated in the 695 figure. Source data is provided in **Supplementary Table S2**.

## 697 EXTENDED DATA FIGURES

698 Extended Data Figure 1: Overview of genome-wide SARS-CoV-2 mutations found in 699 diagnostic nasal biospecimen. The mutations present across the complete SARS-CoV-2 genome 700 are shown. Nucleotide substitutions observed in sequential specimens obtained from patient 1 (P1) 701 with prolonged infection with BA.1 and forward transmission cases (P2, P3 and P4). There is 702 accumulation and fixation of new SNVs in the spike region in P1. The same constellation of 703 mutations was subsequently detected in three documented transmission cases (P2, P3 and P4) and 704 in two sequences from GISAID (EPI ISL 11628400 and EPI ISL 11696379). The only shared synonymous SNV outside of the spike (ORF1a:T6001C) is indicated with an arrow. The number 705 706 of days since the first positive test in P1 is shown on the left, with the number of days after the 707 first positive test for each patient between brackets. The BA.1 substitutions are shown in blue and

novel substitutions are shown in red, relative to the reference genome sequence NC\_045512.2.

# 709 Extended Data Figure 2: Summary of SARS-CoV-2 mutations within the spike gene in

# 710 minority viral populations.

711 The distribution of minority intrahost single nucleotide variants (mSNV) for positions that were

fixed over the course of the infection of the index and transmitted infections are shown indicated

vith asterisks. Single nucleotide variants are colored by strain. The dotted bars indicate positions

vith coverage below the threshold of 100X coverage for calling mSNVs. The positions with

715 minority variants present at frequencies > 0.1 are indicated with triangles for their respective

716 samples.

## 718 Extended Data Figure 3: Summary of genome-wide SARS-CoV-2 mutations in minority

## 719 viral populations for patient P3

720 Similar to Extended Data Fig. 2 but showing the distribution of nucleotide variants below the

721 consensus level observed in one or more specimens from P3. Single nucleotide variants (SNVs)

are colored by strain. The dotted bars indicate positions with coverage below the threshold of 100X

coverage for calling mSNVs. The positions with minority variants present at frequencies > 0.1%

724 are indicated with triangles (nonsynonymous) or circles (synonymous) for their respective

samples.

## 726 Extended Data Figure 4: Summary of SARS-CoV-2 mutations within the Spike gene in

## 727 minority viral populations for patient P3

- 728 Similar to Extended Data Fig. 3 but showing minority mutations in the Spike gene region. Single
- nucleotide variants (SNVs) are colored by strain. The dotted bars indicate positions with coverage
- 730 below the threshold of 100X coverage for calling minor SNVs (mSNVs). The positions with
- 731 minority variants present at frequencies > 0.1 are indicated with triangles for their respective
- 732 samples.
- 733

**Extended Data Figure 1** 



Nonsynonymous mSNV o Synonymous mSNV



Variant Fraction



# **Extended Data Figure 3**

# **Extended Data Figure 4**



Position in SARS-CoV-2 genome (Spike)